Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.80 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.80 |
| ▸ | CA1 | P00915 | 1/20 | 0.68 |
| ▸ | CA2 | P00918 | 1/20 | 0.68 |
| ▸ | CA9 | Q16790 | 1/20 | 0.68 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL216745 | 0.94 | PTGS2 (0.89) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL8126154 | 0.91 | CYP2C9 (0.70) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL18826381 | 0.90 | PTGS2 (0.82) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL18180789 | 0.89 | PTGS2 (0.71) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL213881 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL8113323 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL18180817 | 0.87 | CYP2C9 (0.80) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL20044910 | 0.87 | PTGS2 (0.70) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL20042416 | 0.86 | CYP2C9 (0.78) | PTGS2PTGS1CA1CA2CA9 | |
| SCHEMBL6452272 | 0.85 | PTGS2 (0.92) | PTGS2PTGS1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11202773-B2 | Locally bioavailable drugs | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-12-21 | — | — | US | disclosed |
| US-20180098965-A1 | LOCALLY BIOAVAILABLE DRUGS | UNIVERSITY OF HOUSTON SYSTEM (US) | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180098965-A1 | LOCALLY BIOAVAILABLE DRUGS | ABCG2, FABP1, FABP2 | PTGS2 3366/4885PTGS1 3087/4885CA1 3736/4885 |
| US-11202773-B2 | Locally bioavailable drugs | ABCG2, FABP1, FABP2 | PTGS2 3366/4885PTGS1 3087/4885CA1 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.